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Abstract
Background: Investigating the size and mechanisms of the placebo response in clinical trials have relied on
experimental procedures that simulate the double-blind randomized placebo-controlled design. However, as the
conventional design is thought to elucidate drug rather than placebo actions, different methodological procedures
are needed for the placebo response.
Methods: We reviewed the respective literature for trials designs that may be used to elucidate the size of the
placebo response and the mechanisms associated with it.
Results: In general, this can be done by either manipulation the information provided to the subjects, or by
manipulation the timing of the drug applied. Two examples of each strategy are discussed: the “balanced placebo
design” (BDP) and the “balanced cross-over design” (BCD) and their variants are based on false information, while
the “hidden treatment” (HT) and the “"delayed response test” (DRT) are based on manipulating the time of drug
action. Since most such approaches include deception or incomplete information of the subjects they are suitable
for patient only with authorized deception.
Conclusion: Both manipulating the information provided to subjects (BDP, DCD) or manipulating the timing of
drug application (HT, DRT) allows overcoming some of the restrictions of conventional drug trials in the
assessment of the placebo response, but they are feasible mostly in healthy subjects for ethical reasons.
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Review
Placebo response and placebo effect
Ever since the dawn of the first randomized placebo-
controlled trials testing new drugs and treatments in the
middle of the last century, and even before [1], placebo
responses in clinical trials have given rise to discussion
and concern regarding their mechanisms, and have
usually been regarded as a nuisance or a barrier to a
rational approach in modern drug development. High
placebo responses have induced false expectations
regarding drug efficacy and resulted in the refusal or
withdrawal of drugs in some cases, e.g. neurokinins in
the treatment of depression.
Not only do placebo responses in clinical trials impose
significant limits to the testing of new compounds, but
they are also linked to the drug adherence and compli-
ance of patients in such trials in a paradoxical way.
Patients that adhered to medication instructions by
more than 80% showed better survival in a coronary dis-
ease study, and poor drug adherence in a myocardial
infarction survivor study was associated with a higher
risk of mortality [2] irrespective of whether the active
compound or a placebo was taken, and regardless of
other potential risk factors. This has been attributed to
the greater expectancies or beliefs, both in drug and pla-
cebo responders that the medication may be of help,
although other factors, such as health behaviors, cannot
be ruled out completely. These findings have certainly
fostered the development of further experimental
approaches to the placebo phenomenon [3].
Attempts to unravel the mechanisms of the placebo
response in clinical trials have used meta-analytic
approaches of the placebo arm of trials - with mixed
results. The drug-placebo difference in randomized
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functional disorders [4] but lower in depression (29%),
bipolar mania (31%) and migraine (21%) [5,6]. The rea-
sons for these variable placebo effect rates are unknown
but may include the sample size [4], the year of study
[7], design characteristics [6], and recruitment pattern
[8]. Meta-analyses can come to opposite conclusions on
the same data set, e.g. with respect to the direction of
the effects of the number of study visits on the placebo
effect size [9,10], but this may be due to data extraction
errors that lead to false findings and conclusions [11].
Other contributing factors to the placebo response rate
in clinical trials were: the origin of patients - response
rates in migraine prophylaxis were higher in Europeans
than in North Americans [6] - personal expectations
[12] and the loss thereof, e.g. in Alzheimer’s disease
[13], the study center [14], and patient recruitment and
physician training [8]. A genetic contribution to placebo
responsiveness has been shown [15] but strong empiri-
cal evidence is still lacking.
Because of the difficulties to reliably identify placebo
responders and predicting placebo response rates in
clinical and experimental trials, different methodological
attempts have been made to the way (novel) drugs are
tested against placebo. At the same time, but to a vary-
ing degree, these and other designs have also be used to
unravel some of the mechanisms behind the placebo
response. This review will discuss experimental designs
that may allow characterization and quantification the
placebo response. We will introduce two distinctly dif-
ferent approaches to elucidate the mechanisms behind
this response, i.e. by manipulating the information pro-
vided to participants and by manipulating the timing of
drug action, and will present examples for both from
the current literature.
Throughout this review we will use the following ter-
minology: placebo response is the response observed in
patients receiving a placebo treatment in a trial, which
is measured by within-group changes. Placebo effect, in
contrast, is the effect attributable to the placebo treat-
ment after controlling for other non-specific or extra-
neous factors such as the natural history and regression
to the mean; this is measured by the difference between
a placebo group and a no-treatment control group in a
trial [16]. Thus, the placebo response is expected to be
larger than the placebo effect, and the difference
between both is explained by other factors. Our review
will not focus on designs for better discrimination
between the drug and the placebo effect in clinical trials.
Traditional designs
The most traditional way to attempt to “control” for
placebo response in clinical trials was the use of a cross-
over design, in which an individual patient serves as
her/his own control, reducing the between-subject varia-
bility and the number of patients studied. Data from
crossover trials can also be used to identify predictors of
the placebo response in various clinical conditions.
This model was almost completely abolished due to
the fact that blinding may be rather difficult in such stu-
dies [17,18]. Although “active placebos” that mimic the
side effects of a compound without inducing its main
effects have been used to avoid such problem [19], this
approach can sometimes introduce bias into trials given
that some “active placebos” may not be inert [18].
Another major limitation of the crossover design is the
interference of learning effects: prior exposure to drug
influences the effects of subsequent treatment and prior
exposure to placebo may affect drug efficacy [20,21].
Another conventional model to rule out placebo
responses is the use of a placebo run-in phase prior to
drug and placebo dispensing to identify and exclude pla-
cebo responders: Placebo responders tend to exhibit less
severe symptoms during run-in [22-25], and to respond
faster to treatment with symptom improvement [26]
than patients in the drug arm. Drug-free run-in periods
have also been used to identify individual and group
characteristics of placebo responders. However, these
results cannot be generalized across medical conditions
[24,27] since most of the variables that are regularly
documented at study initiation are related to symptoms
and disease characteristics rather than to individual per-
sonality traits or states [28]. Extensions of placebo run-
in periods are studies with multiple drug/placebo phases
that alternate, with or without washout periods in-
between [29]. These models were more recently
requested again by drug approval authorities to account
for variable symptom courses and the alternation of
symptom-free with relapse periods in many chronic dis-
eases. It has, however, been shown that the placebo
response in a first medication period does not reliably
predict the response (to drug or placebo) in a second
phase [30].
If being a placebo responder is a stable characteristic
of an individual patient - which some of the published
data question - study designs should take this into
account by employing a design with multiple (>2) cross-
overs between placebo and drug, and to randomize and
individualize in a “single subject trials” (SST) the timing
for run-in and run-out for each phase [31]. In theory,
this should allow to reliably distinguish placebo respon-
ders from non-responders. However, multiple crossovers
with randomly assigned treatment periods, with a com-
plete random order or a random starting day may gen-
erate specific methodological problems and need new
statistical models before being applicable in clinical drug
testing. One such novel clinical model was tested
recently in the therapy of Parkinson’s Disease called the
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mized-start design) [32].
While all of these designs may be able to improve
drug testing and the distinction between drug and pla-
cebo response, most of these designs are not able to
characterize the nature of the placebo response and the
mechanisms behind it. Even meta-analyses of the pla-
cebo arms of drug trials as discussed above will only
allow describing potential predictors of the placebo
response that need prospective validation in experimen-
tal or clinical settings.
Experimental designs
In laboratory research, a number of experimental designs
have been employed that may help to identify and char-
acterize predictors of the placebo response in the future.
They have been generated by theoretical issues such as
the “additive model” as discussed by Kirsch 2000 [33].
Some of these models have already been tested in labora-
tory settings, while others are based on theoretical con-
siderations and wait for their empirical approval.
Different from clinical trials, experimental designs allow
control over some of the factors that are believed to drive
the placebo response, e.g. the wording and timing of
information provided [34], the gender and social status of
the experimenter and the subject [35], their emotional
state [36] and psychological and genetic traits [15,37].
The problem of the “additive-model” assumption
Randomized and placebo-controlled clinical trials
usually operate under the assumption that drug and pla-
cebo effects are additive in the drug arm of the study
(Figure 1), thus subtracting the response in the placebo
arm of the study from the response in the drug arm
would allow to assess the “true” drug efficacy. This
assumption is inherent in all current drug trials and is
present also in most experimental studies.
This model has, however, been questioned [38]. One
argument against the additive model is incomplete
blinding with many drugs, so that patients/subjects may
be aware of the experimental condition by taking
adverse events into account. This would increase the
placebo response in the drug group and reduce the pla-
cebo response in the placebo group. Recently, neurobio-
logical evidence against the additive model has been
provided [39] and is summarized elsewhere [40].
Therefore, Kirsch & Weixel [38] and Kirsch [33] pro-
posed the “balanced placebo design” as an answer to
this open question.
The balanced placebo design (BPD)
The so-called “balanced placebo design” (BPD) was tra-
ditionally used in the testing for expectancy effects of
frequently consumed everyday-drugs such as caffeine,
nicotine and alcohol [41], recently also with drugs such
as marijuana [42].
While one half of the study sample receives placebo
and the other half the drug, half of each group is receiv-
ing correct information while the other half is receiving
false information on the nature of their study condition
(drug or placebo) immediately prior to drug testing,
thus allowing to differentiate between the “true” drug
response (those receiving the drug but are told they
received placebo) and the true placebo response (those
receiving placebo but are told they received the drug).
The “non-additive model” according to Kirsch [33]
c a nb et e s t e di nt h ef o l l o w i n gw a y :I ft h ed i f f e r e n c e
between the drug response plus the placebo response
and true drug response is unequal to the true placebo
response, the non-additive assumption is correct.
A variant of the BPD is the “half BPD” in which all
subjects are given placebos, but half of them receive
information that they receive the drug - this is the most
common design in current placebo research, as it does
not require approval for performing a drug study. How-
ever, effective double blinding of such as study is diffi-
cult unless - as in a recent test in our laboratory - the
subjects and the experimenter(s) conducting the study
are made to believe that they participate in a full BPD.
As is evident, BPD studies imply deception of the sub-
jects [43]. This limits its suitability and acceptance out-
side the laboratory and in patients for ethical reasons
[44] unless the proposed “authorized deception” is
implemented. It has recently been shown in an experi-
mental placebo analgesia trial that authorized deception
will not corrupt the data collection [45].
One of the pitfalls of the BPD is the fact that all sub-
jects are informed (either correctly or falsely) prior to
testing whether and what they have received. In scepti-
cal subjects (especially medical students), this may raise
doubts about the truth of the information provided and
may require additional measures, such as a reliable
“cover story” about the rational why the information is
given at all. This is usually done by informing them that
once the drug is active, the information whether and
what they received may no longer be relevant - however,
the subjects’ acceptance of such information is difficult
to prove prior to the test, and its testing afterwards may
be subject to another bias.
The balanced cross-over design (BCD)
In an attempt to overcome the serious limitations of the
BPD, we designed another strategy that may account for
some of the BDP limitations. In this case, subjects are
divided into four groups, and all are told they participate
in a conventional randomized double-blinded and pla-
cebo-controlled crossover trial, in which they will receive
both the drug and the placebo at two different occasions
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group 2/3 will be exposed to drug and placebo in a
balanced way, that is half the subjects will receive the drug
first and the placebo at the second occasion, while the
other half will receive first placebo and then the drug.
Group 1 will receive drug - drug, and Group 4 will receive
placebo - placebo instead (Figure 2).
In this case, Groups 2 and 3 represent the conven-
tional drug trial assuming the “additive model” for drug
and placebo response. In Group 1, the minimal value of
both measures represents the “true” drug response, and
the difference between both is the expectancy compo-
nent of the drug response. In Group 4, the maximum
value should represent the “true” placebo response; and
the difference between both values should be the expec-
tancy component of the placebo response. Comparing
these expectancy effects between groups 1 and 4 allows
to test whether the expectancy component of the pla-
cebo response is equal under drug and placebo condi-
tion - which is the assumption of the “additive model”.
The BCD has one important methodological limita-
tion: As with other crossover designs, interference of
learning effects need to be kept in mind [20,21], and
any adaptation or habituation between measurement 1
and measurement 2 should be minimized, e.g. by
increasing the time interval between the two. Its ethical
limitations (deception) are similar to those of the BPD
with the exception, that subjects may receive a drug
t w i c eb u te x p e c ti tt or e c e i v eo n l yo n c e-a n yr i s k
involved in such a repetition of drug application would
exclude the BCD from use, and it can only be used in
patients when the deception is authorized [43].
To our knowledge, this design has not been used so
far in any research, whether related to drug or to the
placebo response.
“Hidden treatment” according to Benedetti
While most designs and attempts to modify the
response to a drug and explore the placebo response (as
those discussed above) manipulate the information
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Figure 1 The “additive model” and the “non-additive model” according to Kirsch (2000): All placebo-controlled drug trial are currently
based on the assumption that the placebo response in the drug arm of the study is equal to the placebo response in the placebo arm;
however, it may be either smaller or greater.
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den treatment” paradigm [46] manipulate the timing of
the drug action to identify whether and to what degree
the placebo response can be elucidated.
Hidden treatment (HT) or covert treatment is an
option that may be specifically useful for the test of
drug effects in acute and highly symptomatic conditions
such as with postoperative pain [47], anxiety, and motor
d y s f u n c t i o ni nP a r k i n s o n ’s disease [48,49]. It resembles
some of the features of the “single subject trials” [31]. In
case of HT, the patient receives a drug unnoticed in
terms of timing and dosage, and the drug effect (or its
missing action) can be determined independent of the
patient’s expectations. Benedetti and colleagues demon-
strated that under these circumstances drugs commonly
believed to have analgesic properties such as CCK-
antagonists failed to show any anti-nociceptive effects
[50]. Evidently, HT can only be applied with the patient
being fully informed prior to the test that she/he will
receive the drug in any case but will not be informed
about when the drug is provided, otherwise the
approach may raise other ethical concerns [51], espe-
cially with the test of novel compounds of unknown
properties.
The “delayed response” test
A very unique approach based on such an assumption
that has - to our knowledge - never been explored in
any placebo testing is the following: Assume that a drug
can elicit its action at a predefined time point hours
after ingestion, either via a coating technology [52] or a
radio-transmitted mechanical capsule technology [53]
for controlled release of the compound; such technology
has been used in many clinical conditions such as
diabetes, Alzheimer dementia and other conditions. In
this case, a three-arm design (Figure 3) would allow a
very elegant prove of the additive versus non-additive
model of the placebo response.
All subjects receive the same information that they
will receive either a drug or placebo in a double-blinded
fashion, and no information is given about the timing of
drug action; instead, a rational ("cover story”)i sp r o -
vided for prolonged drug action monitoring, e.g. for 24
hours.
Group 1 will receive the drug with immediate action,
group 2 the respective placebo. Group 3 receives the
delayed response medication, e.g. with drug release after
12 hours. To confirm the “non-additive model” (P1 ≠
P2), M1 + P1 ≠ M2 + P3, with P3 = P2 and M1 = M2.
A variant of such a design that intended to elucidate
the drug response in a clinical trial in Parkinson’sD i s -
ease was recently described [32]. While this has never
been used in a laboratory setup for assessment of the
placebo response, preliminary approval of the underlying
hypothesis may be drawn from clinical studies that have
used the delayed release technology in the treatment of
patients, e.g. in 5-ASA treatment of chronic inflamma-
tory bowel diseases [54]: in these studies, the placebo
response should be overall lower as compared to
immediate release medication. Unfortunately, the num-
ber of placebo-controlled studies using such technology
is so far rather low to allow a reliable metaanalytic
comparison.
Conclusions
Investigating the size and mechanisms of the placebo
response in different medical conditions has relied on
experimental procedures that simulate the double-blind
Figure 2 The “balanced cross-over design” (BCD): All subjects are told they participate in a double-blind cross-over design study and will
receive both drug and placebo; this is true for groups 2 and 3, while in groups 1 and 4 they receive drug - drug and placebo - placebo,
respectively.
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However, as the conventional design is thought to eluci-
date drug rather than placebo actions, different metho-
dological procedures are needed for the placebo
response. In general, this can be done by either manipu-
lation the information provided to the subjects, or by
manipulation the timing of the drug applied. Two exam-
ples of each strategy are discussed: the “balanced pla-
cebo design” (BDP) and the “balanced cross-over
design” (BCD) and their variants are based on false
information provided, while the “hidden treatment”
(HT) strategy and the “delayed response test” (DRT) are
based on altering the timing of drug action. While most
such approaches include deception of the subjects this
limitation can be overcome by implementing “author-
ized deception”.
Acknowledgements
We are indebted to a group of young psychosomatic residents (Marc-Andre
Wulf, Anne Grimm, Ulrike Dinger, Jonas Tesarz and others) for their unique
design called “delayed response test” here that was developed during a
group session of the 2009/2010 “Carus Training Program” of the German
College of Psychosomatic Medicine (DKPM).
Supported by a grant from Volkswagen Foundation (I/83 805) to PE.
Author details
1University Hospital Tübingen, Dept. of Psychosomatic Medicine, Tübingen,
Germany.
2University of Düsseldorf, Institute for Clinical Neurobiology and
Medical Psychology, Düsseldorf, Germany.
Authors’ contributions
PE and SK developed the idea for this manuscript, reviewed the respective
literature, discussed the potentials of alternatives to traditional trial designs,
PE wrote the manuscript, and SZ helped writing the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 September 2010 Accepted: 10 June 2011
Published: 10 June 2011
References
1. Hill AB: Suspended judgment: memories of the British streptomycin trial
in tuberculosis. The first randomized clinical trial. Controlled Clinical Trials
1990, 11:77-79.
2. Coronary Drug Project Research Group: Influence of adherence to
treatment and response of cholesterol on mortality in the coronary drug
project. N Engl J Med 1980, 303:1038-1041.
Figure 3 The “delayed response test” (DRT) design: The “additive model” by Kirsch (2000) assumes that P1 = P2.U n d e rt h ef u r t h e r
assumptions that M1 = M2 and P2 = P3, the hypothesis of the “additive model” is falsified if (M1+ P1 ≠ M2 + P3).
Enck et al. BMC Medical Research Methodology 2011, 11:90
http://www.biomedcentral.com/1471-2288/11/90
Page 6 of 83. Enck P, Benedetti F, Schedlowski M: New insights into the placebo and
nocebo responses. Neuron 2008, 59:195-206.
4. Enck P, Klosterhalfen S: The placebo response in functional bowel
disorders: perspectives and putative mechanisms. Neurogastroenterol
Motil 2005, 17:325-31.
5. Sysko R, Walsh BT: A systematic review of placebo response in studies of
bipolar mania. J Clin Psychiatry 2007, 68:1213-127.
6. Macedo A, Banos JE, Farre M: Placebo response in the prophylaxis of
migraine: A meta-analysis. Eur J Pain 2008, 12:68-75.
7. Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of
major depression - variable, substantial, and growing. JAMA
287:1840-1847.
8. Kobak KA, Kane JM, Thase ME, Nierenberg AA: Why do clinical trials fail?
The problem of measurement error in clinical trials: time to test new
paradigms? J Clin Psychopharmacol 2007, 27:1-5.
9. Pitz M, Cheang M, Bernstein CN: Defining the predictors of the placebo
response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005,
3:237-247.
10. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L,
Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ: The placebo
effect in irritable bowel syndrome trials: a meta-analysis.
Neurogastroenterol Motil 2005, 17:332-340.
11. Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B: Data extraction errors in
meta-analyses that use standardized mean differences. JAMA 2007,
298:430-437.
12. Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B,
Willich SN, Melchart D: The impact of patient expectations on outcomes
in four randomized controlled trials of acupuncture in patients with
chronic pain. Pain 2007, 128:264-271.
13. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I,
Asteggiano G: Loss of expectation-related mechanisms in Alzheimer’s
disease makes analgesic therapies less effective. Pain 2006, 121:133-144.
14. Ondo WG: Placebo response in Parkinson trials using patient diaries:
sites do matter. Clin Neuropharmacol 2007, 30:301-304.
15. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linnman C, Pissiota A,
Frans O, Bani M, Bettica P, Pich EM, Jacobsson E, Wahlstedt K, Oreland L,
Långström B, Eriksson E, Fredrikson M: A link between serotonin-related
gene polymorphisms, amygdala activity, and placebo-induced relief
from social anxiety. J Neurosci 2008, 28:13066-13074.
16. Ernst E, Resch KL: Concept of true and perceived placebo effects. BMJ
1995, 311:551-553.
17. Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A,
Ravaud P: Methods of blinding in reports of randomized controlled trials
assessing pharmacologic treatments: a systematic review. PLoS Med 2006,
3:e425.
18. Machado LA, Kamper SJ, Herbert RD, Maher CG, McAuley JH: Imperfect
placebos are common in low back pain trials: a systematic review of the
literature. Eur Spine J 2008, 17:889-904.
19. Edward SJ, Stevens AJ, Braunholtz DA, Lilford RJ, Swift T: The ethics of
placebo-controlled trials: a comparison of inert and active placebo
controls. World J Surg 2005, 29:610-614.
20. Suchman AL, Ader R: Classic conditioning and placebo effects in
crossover studies. Clin Pharmacol Ther 1992, 52:372-377.
21. Colloca L, Benedetti F: How prior experience shapes placebo analgesia.
Pain 2006, 124:126-133.
22. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in
randomized controlled trials of antidepressants for pediatric major
depressive disorder. Am J Psychiatry 2008, 166:42-49.
23. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT:
Initial severity and antidepressant benefits: a meta-analysis of data
submitted to the Food and Drug Administration. PLoS Med 2008, 5:e45.
24. Enck P, Vinson B, Malfertheiner P, Zipfel S, Klosterhalfen S: Placebo effects
in functional dyspepsia - reanalysis of trial data. Neurogastroenterol Motil
2009, 21:370-377.
25. Philip G, Swern AS, Smugar SS, Pearlman DS: Baseline predictors of
placebo response in exercise-induced bronchoconstriction (EIB): pooled
regression analysis from three studies of montelukast in EIB. J Asthma
2010, 47:935-941.
26. Gomeni R, Merlo-Pich E: Bayesian modelling and ROC analysis to predict
placebo responders using clinical score measured in the initial weeks of
treatment in depression trials. Br J Clin Pharmacol 2007, 63:595-613.
27. Talley NJ, Locke GR, Lahr BD, Zinsmeister AR, Cohard-Radice M, D’Elia TV,
Tack J, Earnest DL: Predictors of the placebo response in functional
dyspepsia. Aliment Pharmacol Ther 2006, 23:923-936.
28. Hyland ME, Whalley B, Geraghty AW: Dispositional predictors of placebo
responding: a motivational interpretation of flower essence and
gratitude therapy. J Psychosom Res 2007, 62:331-340.
29. Kleveland PM, Larsen S, Sandvik L, Kristensen P, Johannessen T, Hafstad PE,
Sandbakken P, Løge I, Fjøsne U, Petersen H: The effect of cimetidine in
non-ulcer dyspepsia. Experience with a multi-cross-over model. Scand J
Gastroenterol 1985, 20:19-24.
30. Tack J, Müller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A,
Schnekenbuehl S, Dunger-Baldauf C, Rueegg P: A randomised controlled
trial assessing the efficacy and safety of repeated tegaserod therapy in
women with irritable bowel syndrome with constipation. Gut 2005,
54:1707-1713.
31. Madsen LG, Bytzer P: Review article: Single subject trials as a research
instrument in gastrointestinal pharmacology. Aliment Pharmacol Ther
2002, 16:189-196.
32. D`Agostino RB: The delayed-start study design. N Engl J Med 2009,
361:1304-1306.
33. Kirsch I: Are drug and placebo effects in depression additive? Biol
Psychiatry 2000, 47:733-735.
34. Flaten M, Simonsen T, Olsen H: Drug-related information generates
placebo and nocebo responses that modify the drug response.
Psychosom Med 1999, 61:250-255.
35. Klosterhalfen S, Kellermann S, Braun S, Kowalski A, Schrauth M, Zipfel S,
Enck P: Gender and the nocebo response following conditioning and
expectancy. J Psychosom Res 2009, 66:323-328.
36. Rakel DP, Hoeft TJ, Barrett BP, Chewning BA, Craig BM, Niu M: Practitioner
empathy and the duration of the common cold. Family Med 2009,
41:494-501.
37. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE: Monoamine
Oxidase A and Catechol-O-Methyltransferase functional polymorphisms
and the placebo response in major depressive disorder. J Clin
Psychopharmacol 2009, 29:372-377.
38. Kirsch I, Weixel LJ: Double-blind versus deceptive administration of a
placebo. Behav Neurosci 1988, 102:319-323.
39. Petrovic P, Kalso E, Petersson KM, Andersson J, Fransson P, Ingvar M: A
prefrontal non-opioid mechanism in placebo analgesia. Pain 2010,
150:59-65.
40. Enck P, Weimer K, Horing B, Klosterhalfen S, Zipfel S: Placebo effects in
clinical trials - more questions than answers. Phil Trans Roy Soc B 2011,
366:1889-1895.
41. Rohsenow DJ, Marlatt GA: The balanced placebo design: methodological
considerations. Addict Behav 1981, 6:107-122.
42. Metrik J, Rohsenow DJ, Monti PM, McGeary J, Cook TA, de Wit H, Haney M,
Kahler CW: Effectiveness of a marijuana expectancy manipulation:
Piloting the balanced-placebo design for marijuana. Exp Clin
Psychopharmacol 2009, 17:217-225.
43. Miller FG, Wendler D, Swartzman LC: Deception in research on the
placebo effect. PLoS Med 2005, 2:e262.
44. Ehni HJ, Wiesing U: International ethical regulations on placebo-use in
clinical trials: a comparative analysis. Bioethics 2008, 22:64-74.
45. Martin AL, Katz J: Inclusion of authorized deception in the informed
consent process does not affect the magnitude of the placebo effect for
experimentally induced pain. Pain 2010, 149:208-215.
46. Colloca L, Lopiano L, Lanotte M, Benedetti F: Overt versus covert
treatment for pain, anxiety, and Parkinson’s disease. Lancet Neurol 2004,
3:679-684.
47. Levine JD, Gordon NC, Smith R, Fields HL: Analgesic responses to
morphine and placebo in individuals with postoperative pain. Pain 1981,
10:379-389.
48. Benedetti F, Colloca L, Lanotte M, Bergamasco B, Torre E, Lopiano L:
Autonomic and emotional responses to open and hidden
stimulations of the human subthalamic region. Brain Res Bull 2004,
63:203-211.
49. Lanotte M, Lopiano L, Torre E, Bergamasco B, Colloca L, Benedetti F:
Expectation enhances autonomic responses to stimulation of the human
subthalamic limbic region. Brain Behav Immun 2005, 19:500-509.
50. Colloca L, Benedetti F: Placebo and painkillers: is mind as real as matter?
Nature Rev Neurosci 2005, 5:545-525.
Enck et al. BMC Medical Research Methodology 2011, 11:90
http://www.biomedcentral.com/1471-2288/11/90
Page 7 of 851. Machado L: Problems with the ‘open-hidden’ paradigm: the debate is
still open and the answer is still hidden. Pain 2005, 117:240-241.
52. Behzadi SS, Toegel S, Viernstein H: Innovations in coating technology.
Recent Pat Drug Deliv Formul 2008, 2:209-230.
53. Twomey K, Marchesi JR: Swallowable capsule technology: current
perspectives and future directions. Endoscopy 2009, 41:357-362.
54. Fernandez-Becker NQ, Moss AC: Improving delivery of aminosalicylates in
ulcerative colitis: effect on patient outcomes. Drugs 2008, 68:1089-1103.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2288/11/90/prepub
doi:10.1186/1471-2288-11-90
Cite this article as: Enck et al.: Novel study designs to investigate the
placebo response. BMC Medical Research Methodology 2011 11:90.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Enck et al. BMC Medical Research Methodology 2011, 11:90
http://www.biomedcentral.com/1471-2288/11/90
Page 8 of 8